Navigation Links
GEN point of view article questions reported costs of drug R&D
Date:7/6/2011

New Rochelle, NY, July 6, 2011A policy specialist and a healthcare economist both say that the oft-quoted cost of $1.32 billion to bring a new drug to market does not hold up to close scrutiny, reports Genetic Engineering & Biotechnology News (GEN). The researchers emphasize that available cost data cannot be trusted because the numbers are subject to numerous internal and external sources of variability, according to the July issue of GEN (http://www.genengnews.com/gen-articles/drug-r-d-costs-questioned/3707).

"With heated discussions still taking place over healthcare reform and a regulatory environment increasingly focused on safety, the GEN point of view piece should serve as an important article for multiple discussions on new drug R&D and commercialization costs," says John Sterling, Editor in Chief of GEN. "We hope that the article leads to an informative debate on this crucial issue of new drug research and development costs."

Donald W. Light, Ph.D., a professor at the University of Medicine and Dentistry of New Jersey and the Lokey visiting professor in human biology at Stanford University, and Rebecca Warburton, Ph.D., an associate professor at the University of Victoria (British Columbia), claim that pharmaceutical firms list their R&D costs as high as possible to garner greater prices for their products. Yet, continue the article's authors, a number of independent review groups report that 85% of new drugs exhibit few if any advantages over existing drugs.

Noting that the "R" in R&D is basically unknown and highly variable, Drs. Light and Warburton estimate that the median development ("D") cost for a new drug in 2000 was about $60 million (ranging from $13 million to $203 million depending on the type of drug) while the median D cost in 2006 was approximately $98 million (ranging from $21 million to $333 million).

For a copy of the July issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering & Biotechnology News (GEN, www.genengnews.com) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, such as news and analysis, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Yale researchers pinpoint reasons for dramatic rise in cesarean births
2. Anaphore Appoints Paul A. Grayson President and CEO
3. Salk scientist Joseph Ecker, appointed as HHMI-GBMF Investigator
4. CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator
5. TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services
6. Scientists use super microscope to pinpoint body’s immunity switch
7. Rices origins point to China, genome researchers conclude
8. Human rules may determine environmental tipping points
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. Viral replicase points to potential cancer therapy
11. ID Analytics Strengthens Management Team With Appointment of Senior Executives
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN point of view article questions reported costs of drug R&D
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, the newest ... participant in the Phase 1 Ventures program, is leveraging regional and federal resources ... Solutions helps physicians make better treatment decisions by quantifying medical imaging using a ...
(Date:6/22/2016)... ALBANY, N.Y. , June 22, ... Albany Molecular Research, Inc. (NASDAQ: AMRI ... technology to produce and sell the first commercially ... analytical standard is manufactured using Teewinot,s patented biosynthetic ... cannabinoid biosynthetic genes in microorganisms for efficient production ...
Breaking Biology Technology: